These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 15363049

  • 1. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?
    Wang AY, Li PK, Lui SF, Sanderson JE.
    Nephrology (Carlton); 2004 Aug; 9(4):190-7. PubMed ID: 15363049
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy.
    Dahlöf B.
    Blood Press Suppl; 1994 Aug; 2():35-40. PubMed ID: 8061844
    [Abstract] [Full Text] [Related]

  • 7. [Left-ventricular hypertrophy as a cardiac risk factor: role of the renin-angiotensin-aldosterone system].
    Erne P.
    Praxis (Bern 1994); 1996 Feb 20; 85(8):227-33. PubMed ID: 8701189
    [Abstract] [Full Text] [Related]

  • 8. Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
    Plante E, Lachance D, Beaudoin J, Champetier S, Roussel E, Arsenault M, Couet J.
    Circ Heart Fail; 2009 Jan 20; 2(1):25-32. PubMed ID: 19808312
    [Abstract] [Full Text] [Related]

  • 9. The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease.
    Sica DA, Gehr TW.
    J Renin Angiotensin Aldosterone Syst; 2002 Dec 20; 3(4):247-54. PubMed ID: 12584668
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy.
    Dahlöf B.
    J Hypertens Suppl; 1993 Apr 20; 11(3):S29-35. PubMed ID: 8315516
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Association between angiotensin converting enzyme gene, chymase gene and regression of left ventricular hypertrophy in patients treated with angiotensin converting enzyme inhibitors].
    He H, Li LM, Cao WH, Liu MZ, Sun NL, Lü J, Hu YH.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Sep 20; 25(9):756-60. PubMed ID: 15555355
    [Abstract] [Full Text] [Related]

  • 15. [ACE inhibition: mechanisms of cardioprotection in heart hypertrophy].
    Motz W, Strauer BE.
    Klin Wochenschr; 1991 Sep 20; 69 Suppl 24():39-43; discussion 43-4. PubMed ID: 1830911
    [Abstract] [Full Text] [Related]

  • 16. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA, Vyssoulis GP, Karpanou EA, Marinakis AG, Barbetseas JD, Zervoudaki AI, Cokkinos DV, Stefanadis CI.
    Blood Press Monit; 2007 Apr 20; 12(2):87-94. PubMed ID: 17353651
    [Abstract] [Full Text] [Related]

  • 17. Left-ventricular hypertrophy and coronary artery disease.
    Pierdomenico SD.
    Am J Hypertens; 2007 Oct 20; 20(10):1036-7. PubMed ID: 17903684
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents.
    Prisant LM.
    Am J Med; 2008 Aug 20; 121(8 Suppl):S8-15. PubMed ID: 18638617
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.